#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3225199	B	Inhibition of human recombinant PARP1 by fluorescence based multiwell assay	Homo sapiens	3	ALA3217609	single protein format	Scientific Literature
2.	ALA3225200	B	Inhibition of mouse recombinant PARP2 assessed as radioactivity incorporated from [adenine-2,8-3H]NAD into proteins by liquid scintillation spectrometry	Mus musculus	3	ALA3217609	single protein format	Scientific Literature
3.	ALA3225201	B	Inhibition of tankyrase-1 function in human HeLa cells	Homo sapiens	3	ALA3217609	cell-based format	Scientific Literature
4.	ALA3225202	B	Inhibition of human PARP1 in HEK293 cells assessed as prevention of in MNNG-induced ATP depletion	Homo sapiens	2	ALA3217609	cell-based format	Scientific Literature
5.	ALA3225203	P	Kinetic aqueous solubility of the compound at pH 7.4 at 23 degC		2	ALA3217609	small-molecule physicochemical format	Scientific Literature
6.	ALA3225204	F	Neuroprotective activity in mouse mixed cortical cells assessed as reduction in oxygen-glucose deprivation-induced LDH release	Mus musculus	2	ALA3217609	cell-based format	Scientific Literature
7.	ALA3225205	F	Neuroprotective activity in transient middle cerebral artery occlusion Sprague-Dawley rat model assessed as reduction in brain infarct volume at 0.1 mg/kg, ip 3 times, starting 4 hrs after occlusion relative to vehicle treated control	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature
8.	ALA3225206	F	Neuroprotective activity in transient middle cerebral artery occlusion Sprague-Dawley rat model assessed as reduction in brain infarct volume at 1 mg/kg, ip 3 times, starting 4 hrs after occlusion relative to vehicle treated control	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature
9.	ALA3225207	F	Neuroprotective activity in transient middle cerebral artery occlusion Sprague-Dawley rat model assessed as reduction in brain infarct volume at 10 mg/kg, ip 3 times, starting 4 hrs after occlusion relative to vehicle treated control	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature
10.	ALA3225208	F	Neuroprotective activity in permanent middle cerebral artery occlusion Sprague-Dawley rat model assessed as reduction in brain infarct volume at 1 mg/kg, iv 3 times at 30 mins, 3.5 hrs and 6 hrs after occlusion relative to vehicle treated control	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature
11.	ALA3225209	P	Permeability of the compound by PAMPA		1	ALA3217609	small-molecule physicochemical format	Scientific Literature
12.	ALA3225210	A	Inhibition of CYP3A4 (unknown origin)	Homo sapiens	1	ALA3217609	single protein format	Scientific Literature
13.	ALA3225211	A	Inhibition of CYP2D6 (unknown origin)	Homo sapiens	1	ALA3217609	single protein format	Scientific Literature
14.	ALA3225212	A	Inhibition of CYP2C9 (unknown origin)	Homo sapiens	1	ALA3217609	single protein format	Scientific Literature
15.	ALA3225213	A	Half life in rat liver microsomes	Rattus norvegicus	1	ALA3217609	assay format	Scientific Literature
16.	ALA3225214	A	Half life in human liver microsomes	Homo sapiens	1	ALA3217609	assay format	Scientific Literature
17.	ALA3223196	A	Clearance in rat hepatocytes assessed per 10'6 cells	Rattus norvegicus	1	ALA3217609	cell-based format	Scientific Literature
18.	ALA3223197	A	Clearance in human hepatocytes assessed per 10'6 cells	Homo sapiens	1	ALA3217609	cell-based format	Scientific Literature
19.	ALA3223198	A	Clearance in Sprague-Dawley rat at 10 mg/kg, iv	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature
20.	ALA3223199	A	Volume of distribution in Sprague-Dawley rat at 10 mg/kg, iv	Rattus norvegicus	1	ALA3217609	organism-based format	Scientific Literature